Journal Mobile Options
Table of Contents
Vol. 202, No. 2, 2001
Issue release date: 2001
Section title: Pharmacology and Treatment
Dermatology 2001;202:119–122
(DOI:10.1159/000051610)

Treatment of Classical Kaposi’s Sarcoma with Gemcitabine

Brambilla L.a · Labianca R.b · Ferrucci S.M.a · Taglioni M.a · Boneschi V.a
aInstitute of Dermatology, State University, IRCCS Ospedale Maggiore Policlinico, Milan, and bUnit of Medical Oncology, Ospedali Riuniti, Bergamo, Italy

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 33.00
Account: USD 23.00

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Pharmacology and Treatment

Published online: 4/9/2001
Issue release date: 2001

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 3

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM

Abstract

Background: Several drugs are active in aggressive classical Kaposi’s sarcoma (CKS); chemotherapeutic agents with fewer side-effects, more rapid response and able to overcome resistance to previous treatment are advisable when treating patients in a second line. Gemcitabine, an analogue of deoxycytidine with cytotoxic activity in the treatment of solid tumours, has been found to have no serious side-effects. Objective: To evaluate the usefulness of treating patients affected by aggressive CKS with gemcytabine. Methods: Twelve patients with a recurrent aggressive form of CKS previously treated with chemotherapy were treated with gemcitabine. The drug was administered intravenously at the dose of 1.2 g/week for 2 weeks, followed by a 1-week interval, until maximal response was reached. Objective responses and toxicity were evaluated according to WHO criteria. Results: Eleven evaluable patients achieved an objective response: CR in 1/11 and PR in 10/11. Toxicity was limited. Conclusion: This study shows the usefulness of treating patients affected with aggressive CKS with gemcitabine, in order to obtain control of the disease and to reduce the related symptoms as well as to overcome a possible resistance to previous treatments.

© 2001 S. Karger AG, Basel


  

Author Contacts

Lucia Brambilla
Istituto di Dermatologia
Via Pace 9
I–20122 Milano (Italy)
Tel. +39 02 55035111, Fax +39 02 55195997, E-Mail aldo.finzi@unimi.it

  

Article Information

Received: Received: August 17, 2000
Accepted: November 2, 2000
Number of Print Pages : 4
Number of Figures : 0, Number of Tables : 3, Number of References : 13

  

Publication Details

Dermatology (International Journal for Clinical and Investigative Dermatology)
Founded as ‘Dermatologische Zeitschrift’ by Oskar Lassar (1893–1907); Continued by Erich Hoffmann (1908–1938), continued as ‘Dermatologica’ (1939–1991), by Wilhelm Lutz (1939–1958), Rudolf Schuppli (1959–1985)
Official Organ of the Swiss Society for Dermatology and Venereology; Official Organ of the Belgian Royal Society for Dermatology and Venereology

Vol. 202, No. 2, Year 2001 (Cover Date: 2001)

Journal Editor: J.-H. Saurat, Geneva.
ISSN: 1018–8665 (print), 1421–9832 (Online)

For additional information: http://www.karger.com/journals/drm


Article / Publication Details

First-Page Preview
Abstract of Pharmacology and Treatment

Published online: 4/9/2001
Issue release date: 2001

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 3

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.